癌症疼痛鞘内药物输注的争议
本文综述癌症疼痛鞘内药物输注治疗中的争议领域,包括鞘内导管尖端位置的重要性、鞘内试验的必要性以及鞘内齐考诺肽和局部麻醉药的作用。文中讨论了各领域的证据,强调提供实用临床指导并指出未来研究的知识空白。
要点
- 鞘内药物输注对难治性癌痛有明确作用,但应用存在知识缺口。
- 争议包括导管尖端位置、鞘内试验必要性及齐考诺肽和局麻药角色。
- 强调提供实用临床指导并指出未来研究方向。
核心结论
- 鞘内药物输注在难治性癌痛管理中作用明确,但在导管尖端位置、鞘内试验必要性及齐考诺肽和局麻药角色方面存在争议和知识缺口。
研究设计与样本
- 综述,检索范围未明确报告。
主要发现
- 癌痛管理进步改善症状控制,但许多患者仍受未控制疼痛困扰。
- 鞘内药物输注应用存在显著知识缺口,涉及导管尖端位置、鞘内试验及药物角色。
临床怎么用
- 临床应关注鞘内药物输注的争议点,并参考文中实用临床指导。
局限性
- 综述指出知识缺口,需未来研究填补。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pain and suffering related to cancer are challenging issues that continue to deserve consideration for treatment optimization. Advances in analgesic management and control of the underlying cancer have improved symptom management, yet many patients still suffer from uncontrolled pain. Intrathecal drug delivery has an established role in the management of refractory cancer pain, but there are significant knowledge gaps in our understanding and application of this therapy. This review addresses several areas of controversy, including the importance of intrathecal catheter tip location, the necessity of an intrathecal trial and the role of intrathecal ziconotide and local anesthetics. In each area, the evidence is discussed, with an emphasis on presenting practical clinical guidance and highlighting deficiencies in our knowledge that are worthy of future investigation.
引用
- Brogan SE, Sindt JE, Odell DW, et al. Controversies in intrathecal drug delivery for cancer pain. Reg Anesth Pain Med. 2022. PMID: 35977779. doi:10.1136/rapm-2022-103770
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。